Colchicine deaths blamed on pharmacy error
NEW YORK, Oct 12 (Reuters) Two recent deaths, and possibly a third, from intravenous colchicine therapy at an alternative medicine clinic were the result of a compounding pharmacy error, health authorities reported in the Morbidity and Mortality Weekly Report.
Intravenous colchicine is an accepted, but not an FDA-approved, treatment for acute gout symptoms. In recent years, however, it has been used by alternative medicine practitioners to treat chronic back pain. The drug has well-known side effects and IV doses higher than the standard 2-4 mg single dose used per gout episode have been linked to life-threatening toxicity.
In the current report, health authorities from poison centers in Washington and Oregon yesterday describe two patients who died after receiving intravenous colchicine for back pain.
Both patients, a 77-year-old woman from Washington and a 56-year-old woman from Oregon, received the treatment from the same alternative medicine clinic in Portland, Oregon.
An investigation into the deaths, which took place between 2006 and 2007, revealed that a measuring error by the Texas compounding pharmacy supplying the clinic resulted in blood colchicine concentrations that were higher than the standard level. In one case, the blood level exceeded the recognized therapeutic level by more than eight-fold.
A third death involving a patient who took colchicine obtained from the same clinic appears to have also resulted from the compounding error, the researchers note. The patient had a history of heart disease and recently had a stent implanted, so colchicine poisoning was not initially suspected.
Since these cases surfaced, all remaining vials of colchicine were removed from the clinic and all colchicine sold or produced by the Texas compounding pharmacy in 2007 have been recalled. No further deaths have been reported.
These
events
''highlight
the
risk
for
serious
health
consequences
from
use
of
IV
colchicine
for
back
pain,''
the
report
concludes,
and
''underscore
the
potentially
fatal
ramifications
of
errors
by
compounding
pharmacies,
which
generally
are
not
subject
to
the
same
oversight
and
manufacturing
practices
as
pharmaceutical
manufacturers.''
REUTERS
NY
HS0924